Abstract 129P
Background
Cancer immunotherapy has revolutionized cancer treatment by harnessing the immune system to target tumors. However, its clinical success is limited by low response rates, typically ∼20%. To address the challenge, we developed a transcriptome-based computational framework aimed at improving the efficacy of immunotherapy.
Methods
We established a computational framework to analyze similarities between transcriptome patterns associated with responsiveness or resistance to cancer immunotherapy. We then applied this computational framework to two applications: identifying predictive biomarkers for immunotherapy response and discovering synergistic compounds for combination therapy with immunotherapy. To identify predictive biomarkers, we investigated genomic and epigenomic changes and the transcriptional impact of gene knockouts or knockdowns that mimic the transcriptome pattern of responders. To identify synergistic compounds for combination therapy, we screened compounds in silico that reverse gene signatures associated with resistance to immunotherapy (e.g., T cell exclusion signature, cancer immune resistance program, and nivolumab resistance signature. Finally, we evaluated our computational results through in vitro and in vivo studies.
Results
Using this approach, we found genomic biomarkers that could enhance immunotherapy response. We also discovered three types of chemical compounds for combination therapy: I) known immunotherapy agents (POC verification), Ⅱ) unknown immunotherapy agents with known MoA (drug repurposing), Ⅲ) four clusters with new chemical structures (new drug candidates). We further studied a compound cluster from (Ⅲ) by reverse-docking and measuring structural similarity to identify potential drug targets. We finally demonstrated that co-administration of the compound with anti-PD1 significantly improved survival in a syngeneic mouse model.
Conclusions
We successfully identified both predictive biomarkers and novel synergistic compounds that enhance the efficacy of cancer immunotherapy. These findings hold promise for improving patient outcomes and developing more effective combination therapies. The newly identified compounds are now progressing through preclinical development.
Legal entity responsible for the study
The authors.
Funding
Korea Institute of Science and Technology Information (KISTI) (K24L2M1C4-01) The National Research Foundation of Korea (NRF-2022R1C1C1006162).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session
Resources:
Abstract
99P - Real-world management of ir-colitis, a Danish 10-year cohort study
Presenter: Soeren Petersen
Session: Poster Display session
Resources:
Abstract
101P - Comparison on the effectiveness of multiple single and double immunotherapy treatments on advanced angiosarcoma patients: Meta analysis & systematic review
Presenter: Enzo Marson
Session: Poster Display session
Resources:
Abstract
102P - A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
Presenter: Saifeng Li
Session: Poster Display session
Resources:
Abstract
103P - Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study
Presenter: zhihua wen
Session: Poster Display session
Resources:
Abstract
104P - The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) as second- or later-line therapy for metastatic non-small cell lung cancer
Presenter: Hualin Chen
Session: Poster Display session
Resources:
Abstract
105P - A retrospective study using machine learning to analyze the effects of VEGFR-TKIs and PD-1 inhibitors as third-line or later treatment in patients with MSS mCRC
Presenter: Shumei Han
Session: Poster Display session
Resources:
Abstract
106P - Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
107P - Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
Presenter: Yulu Peng
Session: Poster Display session
Resources:
Abstract
108P - Transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab versus TACE alone in patients with Barcelona Clinic liver cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis
Presenter: Hongjie Cai
Session: Poster Display session
Resources:
Abstract